Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New bandage for IVs could slash infection risk

NCT ID NCT05741866

Disease control Sponsor: The University of Queensland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a special bandage (dressing) that contains a germ-killing ingredient called chlorhexidine for IV tubes placed in the arm. The goal was to see if it reduces infections and other complications compared to the standard bandage. About 300 patients in Australia and France took part, and researchers checked how well the study procedures worked and how many infections occurred.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

300 people

The number who actually took part.

Started

May 2023

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * PIVC to be inserted with expected dwell \>48 hours * Provided written and informed consent (patient or carer) Australia only • ≥6 years of age (due to size of dressing) France only • ≥18 years of age Exclusion Criteria: * Burned, non-intact or scarred skin at the insertion site * Known allergy to CHG or transparent dressing adhesives * Palliative care patients on end-of-life pathway * Patient who has already participated in the study * Placement of a PIVC in an emergency, that does not allow the usual rules of hygiene for insertion to be adhered to. Additional exclusions to Australian study only * Non-English-speaking patients without interpreter * Under the care of Child and Family Services and unable to gain consent from case worker (paediatric patients) Additional exclusions to French study only * Patients not benefiting from the French Social Security scheme or not benefiting from it through a third party, * Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, adults under legal protection. * Known pregnant or breastfeeding women * Predictably difficult vascular access (IV drug addiction, obesity)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Catheter complications are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Catheter-Related Infections injury phlebitis prosthesis-related infectious disease Wound Infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Catheter complications Catheter infection Catheter related complication Catheter-related infections Device related infection Device related sepsis Device site reactions Occlusive dressings Vascular access complication Wound Wound infection Wound of skin

Contacts and locations

Locations

  • Queensland Children's Hospital

    South Brisbane, Queensland, 4101, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, 4029, Australia

  • University Hospital of Poitiers

    Poitiers, New Aquitaine, 86000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.